XML 59 R48.htm IDEA: XBRL DOCUMENT v3.25.3
Segment (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
Segment Reporting Information [Line Items]          
Number of reporting segments | segment       1  
Revenue:          
Total revenue $ 131,872   $ 115,860 $ 376,509 $ 327,132
Cost of revenue:          
Intangible asset amortization - cost of revenue 2,707   2,917 7,959 8,741
Gross profit 91,282   79,010 260,559 219,391
Operating expenses:          
Total research and development 15,981   17,574 49,965 50,004
Total selling and marketing 24,455   22,612 74,225 70,610
Total general and administrative 27,278   25,742 93,417 83,697
Impairment of assets 0 $ 20,500 185 20,505 614
Other income, net 4,057   (4,831) (6,985) (10,334)
Income tax (benefit) provision (248)   1,693 2,363 3,276
Net income 19,137   15,155 25,204 19,025
Testing revenue          
Revenue:          
Total revenue 127,756   109,536 357,328 306,809
Cost of revenue:          
Cost of revenue 33,777   29,029 94,444 82,928
Product revenue          
Revenue:          
Total revenue 3,301   3,188 10,479 10,631
Cost of revenue:          
Cost of revenue 3,015   1,792 6,186 6,310
Biopharmaceutical and other revenue          
Revenue:          
Total revenue 815   3,136 8,702 9,692
Cost of revenue:          
Cost of revenue 1,091   3,112 7,361 9,762
Intangible Asset Amortization          
Operating expenses:          
Intangible asset amortization - operating expenses 622   880 1,865 2,499
Reportable Segment          
Revenue:          
Total revenue 131,872   115,860 376,509 327,132
Cost of revenue:          
Intangible asset amortization - cost of revenue 2,707   2,917 7,959 8,741
Gross profit 91,282   79,010 260,559 219,391
Operating expenses:          
Total research and development 15,981   17,574 49,965 50,004
Total selling and marketing 24,455   22,612 74,225 70,610
Total general and administrative 27,278   25,742 93,417 83,697
Impairment of assets 0   185 20,505 614
Other income, net 4,057   (4,831) (6,985) (10,334)
Income tax (benefit) provision (248)   1,693 2,363 3,276
Net income 19,137   15,155 25,204 19,025
Reportable Segment | Research and development:          
Operating expenses:          
Compensation expense 9,028   8,906 27,840 26,356
Direct expense 3,512   5,479 10,946 14,596
Other research and development expenses 1,586   1,338 5,278 4,195
Allocation of facilities and IT expenses 1,855   1,851 5,901 4,857
Reportable Segment | Selling and marketing:          
Operating expenses:          
Compensation expense 16,977   15,814 52,214 50,517
Direct expense 1,376   1,427 3,564 4,613
Other selling and marketing expenses 3,332   3,271 10,880 9,897
Allocation of facilities and IT expenses 2,770   2,100 7,567 5,583
Reportable Segment | General and administrative:          
Operating expenses:          
Compensation expense 20,688   18,958 62,121 59,824
Other general and administrative expenses 14,508   14,565 56,132 45,048
Allocation of facilities and IT expenses (7,918)   (7,781) (24,836) (21,175)
Reportable Segment | Testing revenue          
Revenue:          
Total revenue 127,756   109,536 357,328 306,809
Cost of revenue:          
Laboratory supplies and reagents expense 14,766   13,887 43,134 39,131
Sample collection expense 3,078   3,663 9,398 9,884
Compensation expense 6,273   5,743 17,906 16,097
Other cost 6,456   2,797 14,017 9,122
Allocation of facilities and IT expenses 3,204   2,939 9,989 8,694
Cost of revenue 33,777   29,029 94,444 82,928
Reportable Segment | Product revenue          
Revenue:          
Total revenue 3,301   3,188 10,479 10,631
Cost of revenue:          
Product costs 1,050   545 1,864 2,436
License fees and royalties 257   270 888 1,021
Other cost 1,672   750 2,980 2,372
Allocation of facilities and IT expenses 36   227 454 481
Cost of revenue 3,015   1,792 6,186 6,310
Reportable Segment | Biopharmaceutical and other revenue          
Revenue:          
Total revenue 815   3,136 8,702 9,692
Cost of revenue:          
Compensation expense 426   1,424 3,318 4,958
Other cost 612   1,024 3,118 3,244
Allocation of facilities and IT expenses 53   664 925 1,560
Cost of revenue 1,091   3,112 7,361 9,762
Reportable Segment | Intangible Asset Amortization          
Operating expenses:          
Intangible asset amortization - operating expenses $ 622   $ 880 $ 1,865 $ 2,499